Overview
?
MAURIE STANG
See more contacts
Scientific Research and Development Services
,
Medical and Diagnostic Laboratories
,
Professional, Scientific, and Technical Services
,
Commercial physical research
,
Medical laboratories
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
3/11 JULIUS AVENUE NORTH RYDE, NEW SOUTH WALES, 2113 Australia
See other locations
?
?
Estimated
$117
Actual
$3
JUN
?
?
Australian:VBS
?
?
?
Is this your business? Contact us to understand how D&B calculated your company’s specific ESG Ranking, provide new or updated information to ensure your company’s ESG Ranking remains accurate and up to date, or dispute your current ranking.
Contacts
Get in Touch with 6 Principals*
A D&B Hoovers Subscription is your foot in the door to VECTUS BIOSYSTEMS LIMITED contact information.
-
MAURIE STANGDirector
-
??
-
??
-
??
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of June 30, 2020 (12 month period) in USD
Annual Sales 2021
$117
USD
Actual
1 USD = 1.528 AUD
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net Operating Cash | $ | $ | $ |
| Net Investing Cash | $ | $ | $ |
| Net Financing Cash | $4 | $4 | $1 |
| Net Change in Cash | $2 | $2 | $0 |
| Cash at Beginning of Period | $2 | $0 | $0 |
| Cash at End of Period | $4 | $2 | $0 |
| Capital Expenditure | $ | $ | $ |
| Assets (mil) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $4 | $2 | $0 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $0 | $0 | $0 |
| Asset Summary | |||
| Total Current Assets | $4 | $2 | $0 |
| Tangible Fixed Assets | $0 | $0 | $0 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $4 | $2 | $0 |
| Liabilities (mil) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $0 | $1 |
| Short-Term Debt | $0 | $ | $ |
| Other Current Liabilities | $1 | $1 | $1 |
| Liability Summary | |||
| Total Current Liabilities | $1 | $1 | $1 |
| Long-Term Debt | $5 | $5 | $1 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $6 | $6 | $3 |
| Stakeholder's Equity (mil) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Equity | |||
| Common Stock | $16 | $12 | $12 |
| Retained Earnings | -$19 | -$16 | -$14 |
| Equity Summary | |||
| Total Equity | -$2 | -$4 | -$2 |
| Shares Outstanding | 31,655,394 | 23,654,816 | 23,379,996 |
Before You Go
Don't miss your chance for 50 free email contacts and prospecting data right inside of your inbox.
Don't miss your chance for 50 free email contacts and prospecting data right inside of your inbox.